CA2157758A1 - Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine - Google Patents

Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine

Info

Publication number
CA2157758A1
CA2157758A1 CA002157758A CA2157758A CA2157758A1 CA 2157758 A1 CA2157758 A1 CA 2157758A1 CA 002157758 A CA002157758 A CA 002157758A CA 2157758 A CA2157758 A CA 2157758A CA 2157758 A1 CA2157758 A1 CA 2157758A1
Authority
CA
Canada
Prior art keywords
des
que
est
une
les
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002157758A
Other languages
English (en)
French (fr)
Inventor
Louis Chedid
Georges Bahr
Pierre Lefrancier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9303230A external-priority patent/FR2702659B1/fr
Priority claimed from FR9303787A external-priority patent/FR2703251B3/fr
Application filed by Individual filed Critical Individual
Publication of CA2157758A1 publication Critical patent/CA2157758A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/193Colony stimulating factors [CSF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2013IL-2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002157758A 1993-03-19 1994-03-21 Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine Abandoned CA2157758A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
FRFR93/03230 1993-03-19
FR9303230A FR2702659B1 (fr) 1993-03-19 1993-03-19 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
FRFR93/03787 1993-03-31
FR9303787A FR2703251B3 (fr) 1993-03-31 1993-03-31 Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
PCT/FR1994/000307 WO1994021275A1 (fr) 1993-03-19 1994-03-21 Compositions pour l'application en therapeutique humaine, caracterisees par l'association d'un muramyl-peptide a une cytokine

Publications (1)

Publication Number Publication Date
CA2157758A1 true CA2157758A1 (en) 1994-09-29

Family

ID=26230187

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002157758A Abandoned CA2157758A1 (en) 1993-03-19 1994-03-21 Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine

Country Status (11)

Country Link
US (1) US5932208A (ja)
EP (1) EP0689449B1 (ja)
JP (1) JP3723206B2 (ja)
AT (1) ATE226828T1 (ja)
AU (1) AU6285694A (ja)
CA (1) CA2157758A1 (ja)
DE (1) DE69431620T2 (ja)
DK (1) DK0689449T3 (ja)
ES (1) ES2187520T3 (ja)
PT (1) PT689449E (ja)
WO (1) WO1994021275A1 (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4411592A1 (de) 2023-02-06 2024-08-07 Sick Ag Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159460A (en) * 1988-05-27 2000-12-12 Amgen Inc. Method for treating interleukin-1 mediated diseases
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6267968B1 (en) * 1995-04-07 2001-07-31 Vacsyn S.A. MDP derivatives and conjugates having haematipoietic function stimulating activity, and compositions containing same
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Il−1媒介疾患を処置するためにil−1インヒビターを使用する組合せ療法
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
MXPA02009454A (es) 2000-03-31 2003-04-10 Purdue Research Foundation Metodo de tratamiento usando conjugados ligando-inmunogeno.
FR2809106A1 (fr) * 2000-05-17 2001-11-23 Istac Polypeptide ro/ssa-like et ses fragments et polynucleotides codant lesdits polypeptides et applications therapeutiques
AU2002316384A1 (en) * 2001-06-26 2003-03-03 Photomed Technologies, Inc. Multiple wavelength illuminator
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
KR20040053136A (ko) * 2001-09-28 2004-06-23 펄듀 리서치 파운데이션 리간드-면역원 공액체를 이용한 치료 방법
US20030097409A1 (en) * 2001-10-05 2003-05-22 Hungchou Tsai Systems and methods for securing computers
BRPI0314038B8 (pt) 2002-09-06 2021-05-25 Amgen Inc anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
US7546638B2 (en) * 2003-03-18 2009-06-09 Symantec Corporation Automated identification and clean-up of malicious computer code
DK1708690T3 (en) 2003-11-17 2016-11-07 Biomarin Pharm Inc TREATMENT OF PHENYLKETONURI WITH BH4
US8003126B2 (en) * 2004-11-17 2011-08-23 Biomarin Pharmaceutical Inc. Stable tablet formulation
AR056806A1 (es) 2005-11-14 2007-10-24 Amgen Inc Moleculas quimericas de anticuerpo rankl- pth/ pthrp
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US20160000936A1 (en) 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
US10041044B2 (en) 2016-07-29 2018-08-07 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development
EP3836954A1 (en) 2018-08-13 2021-06-23 Iltoo Pharma Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof
WO2023222565A1 (en) 2022-05-16 2023-11-23 Institut National de la Santé et de la Recherche Médicale Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK585886A (da) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd Immunstimulerende middel og anvendelse deraf
IL83350A0 (en) * 1986-08-13 1987-12-31 Takeda Chemical Industries Ltd Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4411592A1 (de) 2023-02-06 2024-08-07 Sick Ag Verfahren zum lesen eines optischen codes und optoelektronischer codeleser

Also Published As

Publication number Publication date
WO1994021275A1 (fr) 1994-09-29
DK0689449T3 (da) 2003-03-03
PT689449E (pt) 2003-03-31
ATE226828T1 (de) 2002-11-15
JPH08511235A (ja) 1996-11-26
ES2187520T3 (es) 2003-06-16
EP0689449A1 (fr) 1996-01-03
EP0689449B1 (fr) 2002-10-30
DE69431620T2 (de) 2003-07-03
US5932208A (en) 1999-08-03
JP3723206B2 (ja) 2005-12-07
AU6285694A (en) 1994-10-11
DE69431620D1 (de) 2002-12-05

Similar Documents

Publication Publication Date Title
CA2157758A1 (en) Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine
Barth et al. The role of adjuvant therapy in melanoma management
CA2111580C (fr) Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
US20130164255A1 (en) Immunotherapy for reversing immune suppression
EP2684569A1 (en) A composition for treatment of advanced prostate cancer
FR2774697A1 (fr) Procede de sensibilisation de cellules presentatrices d'antigene et moyens pour la mise en oeuvre du procede
CA2322712A1 (fr) Methodes d'activation de cellules tueuses naturelles (nk)
Salem et al. Paracrine release of IL-12 stimulates IFN-γ production and dramatically enhances the antigen-specific T cell response after vaccination with a novel peptide-based cancer vaccine
AU2002342151A1 (en) Immunotherapy for reversing immune suppression
US20040120926A1 (en) Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment
Nijen Twilhaar et al. Incorporation of toll-like receptor ligands and inflammasome stimuli in GM3 liposomes to induce dendritic cell maturation and T cell responses
Mullins et al. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation
Agarwala et al. Histamine dihydrochloride: inhibiting oxidants and synergising IL-2-mediated immune activation in the tumour microenvironment
EP0579791B1 (fr) Utilisation d'une composition cellulaire pour le traitement des organismes humains ou animaux
US20210353745A1 (en) Methods and reagents to treat allergy
Prussick et al. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy
US20100197595A1 (en) Treatment of melanoma with alpha thymosin peptides
Lotzová et al. Function of Interleukin-2-Activated NK Cells in Leukemia Resistance and Treatment
WO2001080836A1 (fr) Utilisation de vecteurs particulaires dans l'immunomodulation
FR2703251A1 (fr) Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine .
FR2702659A1 (fr) Compositions pour l'application en thérapeutique humaine, caractérisées par l'association d'un muramyl-peptide à une cytokine.
Bear et al. Biologic therapy of melanoma with cytokines and lymphocytes
McCulloch et al. Lymphokine‐activated killer (LAK) cells modulate the effects of IL‐2 on a T cell‐mediated immune response
EP0819136B1 (fr) Derives et conjugues du mdp presentant une activite stimulatrice de la fonction hematopoietique et composition les contenant
WO2023176896A1 (ja) 糸状菌感染症の治療薬及び糸状菌感染症の治療方法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued